
HippoFi entered into a partnership with Zimmer Biomet to introduce a novel synthetic biomaterial for bone growth, set for a 2024 launch under HippoFi’s biologic subsidiary, PUR Biologics.
HippoFi/PUR gained FDA 510(K) clearance for ActiveOrb technology, and secured from Zimmer Biomet an exclusive global license to the underlying technology for the spine market. Both entities have engaged in a joint commercialization research agreement, with Zimmer Biomet overseeing the production of the spine-specific product under the PUR Biologics brand.
PUR Biologics’ line of biologic products includes allografts and demineralized extracellular matrices, synthetic bone-forming solutions, cellular-derived tissues and a future of patented and next-generation regenerative stem cell and growth factor-driven therapeutics for treating osteoarthritis and cartilage regeneration.
Source: HippoFi, Inc.
HippoFi entered into a partnership with Zimmer Biomet to introduce a novel synthetic biomaterial for bone growth, set for a 2024 launch under HippoFi’s biologic subsidiary, PUR Biologics.
HippoFi/PUR gained FDA 510(K) clearance for ActiveOrb technology, and secured from Zimmer Biomet an exclusive global license to the underlying technology for...
HippoFi entered into a partnership with Zimmer Biomet to introduce a novel synthetic biomaterial for bone growth, set for a 2024 launch under HippoFi’s biologic subsidiary, PUR Biologics.
HippoFi/PUR gained FDA 510(K) clearance for ActiveOrb technology, and secured from Zimmer Biomet an exclusive global license to the underlying technology for the spine market. Both entities have engaged in a joint commercialization research agreement, with Zimmer Biomet overseeing the production of the spine-specific product under the PUR Biologics brand.
PUR Biologics’ line of biologic products includes allografts and demineralized extracellular matrices, synthetic bone-forming solutions, cellular-derived tissues and a future of patented and next-generation regenerative stem cell and growth factor-driven therapeutics for treating osteoarthritis and cartilage regeneration.
Source: HippoFi, Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.